Numis Securities Ltd reaffirmed their buy rating on shares of Horizon Discovery Group PLC (LON:HZD) in a report published on Monday, July 3rd, Marketbeat.com reports. They currently have a GBX 262 ($3.41) price target on the stock.
HZD has been the topic of several other research reports. Panmure Gordon reaffirmed a buy rating and issued a GBX 205 ($2.67) target price on shares of Horizon Discovery Group PLC in a report on Thursday, April 20th. N+1 Singer reissued a buy rating and set a GBX 194 ($2.53) price objective on shares of Horizon Discovery Group PLC in a report on Tuesday, March 14th. Finally, Beaufort Securities reissued a speculative buy rating and set a GBX 200 ($2.61) price objective on shares of Horizon Discovery Group PLC in a report on Wednesday, May 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of GBX 226.20 ($2.95).
Horizon Discovery Group PLC (HZD) remained flat at GBX 256.00 during mid-day trading on Monday. The stock had a trading volume of 3,500 shares. The stock’s market capitalization is GBX 243.83 million. Horizon Discovery Group PLC has a 52 week low of GBX 104.00 and a 52 week high of GBX 275.00. The company’s 50 day moving average price is GBX 215.51 and its 200 day moving average price is GBX 192.42.
COPYRIGHT VIOLATION NOTICE: “Horizon Discovery Group PLC (LON:HZD) Stock Rating Reaffirmed by Numis Securities Ltd” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/07/29/horizon-discovery-group-plcs-lonhzd-buy-rating-reaffirmed-at-numis-securities-ltd-updated-updated-updated.html.
Horizon Discovery Group PLC Company Profile
Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.